Oncotarget

Research Papers:

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era

Qin Wang, Yan Qin, Shengyu Zhou, Xiaohui He, Jianliang Yang, Suyi Kang, Peng Liu, Sheng Yang, Changgong Zhang, Lin Gui, Yuankai Shi _ and Yuankai Shi _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:72219-72228. https://doi.org/10.18632/oncotarget.12663

Metrics: PDF 614 views  |   HTML 853 views  |   ?  


Abstract

Qin Wang1, Yan Qin1, Shengyu Zhou1, Xiaohui He1, Jianliang Yang1, Suyi Kang1, Peng Liu1, Sheng Yang1, Changgong Zhang1, Lin Gui1, Yan Sun1, Yuankai Shi1

1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Correspondence to:

Yuankai Shi, email: syuankai@cicams.ac.cn

Keywords: classical Hodgkin lymphoma, prognosis, international prognostic score, serum beta-2 macroglobulin

Received: September 06, 2016     Accepted: October 07, 2016     Published: October 14, 2016

ABSTRACT

The prognostic value of pretreatment serum beta-2 microglobulin (B2MG) level in advanced Hodgkin lymphoma (HL) patients treated in the modern era has not been well established. We conducted a retrospective study involving 202 advanced classical HL (cHL) patients treated from 1998.5 to 2015.7 to evaluate the impact of serum B2MG level on prognosis. Multivariate analysis showed that serum B2MG level ≥ 2.5 mg/L was an independent predictor for freedom from progression (FFP) (P = 0.001), lymphoma-specific survival (P = 0.030) and overall survival (P = 0.034). The 5-year FFP of patients with serum B2MG level ≥ 2.5 mg/L was 66.8%, compared with 89.7% in patients with B2MG level < 2.5 mg/L (P < 0.001). The traditionally used International Prognostic Score (IPS) remained prognostic for FFP (P = 0.013) but the predictive range narrowed, with 5-year FFP ranging from 90.9% to 62.3%. The 5-year FFP of the 44 patients with both IPS ≥ 3 and serum B2MG ≥ 2.5 mg/L was 50.7%, which was significantly worse than that of the 87 patients with only one of the two factors (81.9%, P < 0.001) or the 71 patients with both B2MG < 2.5 mg/L and IPS < 3 (91.1%, P < 0.001). The difference of FFP between the latter two groups was smaller but also significant (P = 0.038). In summary, our data suggest pretreatment serum B2MG level ≥ 2.5 mg/L was an independent unfavorable prognostic factor in advanced cHL patients treated in the modern era. It improves IPS in predicting the outcomes as the combination of IPS and B2MG indentified a wider prognostic range than IPS alone with a sizable number of patients in different risk groups.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12663